Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Aug 09, 2023 11:59am
57 Views
Post# 35579684

RE:RE:Reading material

RE:RE:Reading material I posted the wrong Arbitration: LCIA.  It should have been: ICDR

ICDR Arbitration

Although the ICDR does not publish its official statistics on the time and cost of arbitration, in the ICDR Time and Cost, Considering the Impact of Settling International Arbitrations Report, the ICDR indicated that the mean duration of arbitration for all ICDR tribunals was 15.4 months, whereas the median duration was 13.1 months. Interestingly, the ICDR Report, which is based on ICDR cases that closed between 1 January 2015 and 31 December 2017, reveals that 72% of ICDR arbitrations settle prior to an award being rendered and that 39% of those settled cases are resolved prior to tribunal fees being incurred. The ICDR considers that it has the quickest mean and mediation duration statistics among the arbitral institutions that publicly report duration statistics with comparable data sets, although the comparison method is not necessarily accurate as it compares different data sets and reporting time periods.

 
<< Previous
Bullboard Posts
Next >>